Mononuclear Therapeutics Passed Regular AABB Assessment

Hong Kong, 15 October 2025 – Mononuclear Therapeutics Limited (MonoTx®) announced that the company has again passed regular the American Association of Blood Banks (AABB) assessment, and obtained Certificate of Accreditation and Cellular Starting Material Qualification.

This company has maintained the accreditations since 2019 and built its public umbilical cord blood mononuclear cell (UCBMNC) bank of international credibility and profile, supplying cellular products to save lives and treat diseases. The company develops regenerative therapies with UCBMNC and other cord blood components for neurological diseases, eye disorders and other conditions.